微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 72.77% | -7.39% | 3.64% | 27/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 70.22% | -9.85% | -1.19% | 32/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 71.06% | -10.05% | -1.88% | 30/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 72.42% | -8.4% | -7.84% | 29/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 78.58% | -2.33% | 0.89% | 21/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 77.89% | -0.93% | -1.41% | 27/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 79% | -0.14% | -0.08% | 26/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 79.06% | -2.65% | -1.73% | 24/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 80.46% | -3.91% | 2.34% | 24/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 78.62% | -6.29% | -0.63% | 23/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 79.11% | -2.94% | -2.59% | 23/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 81.22% | 1.02% | -3% | 22/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 83.73% | 7.37% | -0.2% | 16/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 83.89% | 0.56% | 2.92% | 22/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 81.51% | -0.68% | 1.39% | 20/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 80.4% | 2% | 3.1% | 22/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 77.98% | -2.45% | -6.53% | 18/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 83.43% | 6.45% | 1.66% | 17/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 82.07% | 2% | 2.66% | 16/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 79.94% | 2% | 1.99% | 16/158 | 55.23% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 78.38% | -3.14% | -3.14% | 22/158 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |
| 2018-12-31 | 80.92% | -1.77% | -1.77% | 20/158 | -208.09% | 微芯生物 | 95.81% | 行业排名> |
| 2017-12-31 | 82.38% | 2% | 2% | 13/158 | 52.32% | 微芯生物 | 96.09% | 行业排名> |